AtriCure, Inc. (ATRC)

In the past six months, AtriCure's stock has been influenced by several events, including the First Quarter 2025 Financial Results where the company reported a revenue of $123.6 million, a 13.6% increase year-over-year, and an improved net loss of $6.7 million. The stock experienced a drop of approximately 25% from recent highs. The Second Quarter 2025 Financial Results showed a non-GAAP EPS of -$0.02 and revenue of $136.1 million, surpassing estimates, and the company raised its financial outlook for 2025. AtriCure announced the launch of the cryoXT™ device for post-operative pain management following amputation. The company announced the completion of enrollment in the LeAAPS Clinical Trial for stroke prevention and the first patient treated in the BoxX-NoAF clinical trial. AtriCure is scheduled to release its third-quarter 2025 financial results and participate in investor conferences.

No specific information regarding demand seasonality for AtriCure, Inc.'s products and services was found in the provided search results. The company's revenue drivers are generally tied to the volume of surgical procedures utilizing its products and reimbursement rates.

AtriCure, Inc. is a medical device company specializing in surgical solutions for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, operating within the Healthcare sector, specifically in the Medical Instruments & Supplies and Surgical Devices industry. Its major products include Surgical Ablation Devices like the Isolator Synergy Ablation System and CryoICE Cryoablation System, the AtriClip Left Atrial Appendage Exclusion System for LAA management, and cryoSPHERE and cryoXT probes for post-operative pain management. The company also offers the EPi-Sense Systems, the LARIAT System, Lumitip dissectors, Glidepath guides, Subtle Cannula's, reusable cardiac surgery instruments, and Hybrid AF Therapy.

AtriCure is headquartered in Mason, Ohio, USA, with additional offices in Minnetonka, Minnesota, and Pleasanton, California. It has a growing global presence with offices and subsidiaries in Canada, the United Kingdom, Germany, the Netherlands, Japan, China (Beijing), and Hong Kong. The company sells its products in the United States, the Asia-Pacific region, and internationally through a direct sales force and distributors.

In the past year, AtriCure has received positive recognition for its workplace culture, being named one of the "Best Companies to Work For" by U.S. News and World Report in October 2025. The company has also been actively covered in the media for various company updates, with 22 out of 30 media events in the last year being about company updates. There have been no significant negative events impacting AtriCure's brand reputation reported in the past year.

AtriCure, Inc.'s ownership is primarily composed of institutional investors, who hold a substantial portion of the outstanding shares (approximately 99.11% to 100.54%). Major institutional owners include WCM Investment Management LLC, Truist Financial Corp, First Bank & Trust, and Osterweis Capital Management Inc. Individual investors and company executives also hold shares.